Ipilimumab is monoclonal antibody against :
## **Core Concept**
Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor. It works by targeting a specific protein receptor that plays a crucial role in regulating the immune response. This receptor is involved in the downregulation of immune responses, and by inhibiting it, ipilimumab enhances the body's immune response against cancer cells.
## **Why the Correct Answer is Right**
The correct answer, CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4), is a protein receptor that downregulates the immune system by binding to B7 molecules on antigen-presenting cells. By inhibiting CTLA-4 using ipilimumab, the immune response against cancer cells is enhanced, allowing for increased T-cell activation and proliferation. This mechanism is critical in the treatment of certain types of cancer, such as metastatic melanoma.
## **Why Each Wrong Option is Incorrect**
- **Option A:** PD-1 (Programmed Death-1) is another immune checkpoint protein, but it is targeted by different monoclonal antibodies like nivolumab and pembrolizumab, not ipilimumab.
- **Option B:** LAG-3 (Lymphocyte-Activation Gene 3) is also an immune checkpoint protein but is not the target of ipilimumab.
- **Option D:** TIM-3 (T-cell Immunoglobulin and Mucin-3) is another checkpoint molecule involved in immune regulation but is not targeted by ipilimumab.
## **Clinical Pearl / High-Yield Fact**
Ipilimumab is specifically used in the treatment of advanced melanoma and has been shown to improve survival in patients with this condition. A notable side effect of ipilimumab is the risk of immune-related adverse events (irAEs), which can be severe and require prompt management.
## **Correct Answer:** C. CTLA-4.